Piper Jaffray Reaffirms “Overweight” Rating for Sarepta Therapeutics (SRPT)

Piper Jaffray reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Monday, March 12th. Piper Jaffray currently has a $76.12 price objective on the biotechnology company’s stock, down from their prior price objective of $83.00.

Several other brokerages have also recently issued reports on SRPT. SunTrust Banks raised their target price on shares of Sarepta Therapeutics to $76.00 and gave the stock a buy rating in a report on Thursday, March 8th. Morgan Stanley raised their target price on shares of Sarepta Therapeutics from $63.00 to $64.00 and gave the stock an overweight rating in a report on Tuesday, March 6th. Credit Suisse Group set a $81.00 target price on shares of Sarepta Therapeutics and gave the stock a buy rating in a report on Friday, March 2nd. Barclays reiterated a hold rating and issued a $55.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, January 23rd. Finally, William Blair reiterated an outperform rating on shares of Sarepta Therapeutics in a report on Monday, February 5th. Five research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $76.40.

How to Become a New Pot Stock Millionaire

NASDAQ SRPT traded down $1.12 on Monday, reaching $71.74. 759,523 shares of the company’s stock traded hands, compared to its average volume of 1,565,732. Sarepta Therapeutics has a 12 month low of $28.14 and a 12 month high of $84.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96. The stock has a market capitalization of $4,805.80, a P/E ratio of -43.74 and a beta of 1.29.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The firm had revenue of $57.30 million during the quarter, compared to the consensus estimate of $57.33 million. During the same quarter in the prior year, the business posted ($0.71) EPS. The firm’s revenue for the quarter was up 961.1% on a year-over-year basis. equities analysts expect that Sarepta Therapeutics will post -1.18 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in SRPT. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Sarepta Therapeutics by 39.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 977 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its position in Sarepta Therapeutics by 140.9% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 2,493 shares during the period. Prentiss Smith & Co. Inc. purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $199,000. Brighton Jones LLC purchased a new position in Sarepta Therapeutics during the third quarter valued at $211,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $217,000. 84.98% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by BBNS and is owned by of BBNS. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://baseballnewssource.com/2018/04/06/sarepta-therapeutics-srpt-given-overweight-rating-at-piper-jaffray-companies/2037393.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry


Leave a Reply

 
© 2006-2018 BBNS.